ACP
SWTX

Altitude Crest Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Altitude Crest Partners’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-128,842
Closed -$6.34M – 25
2024
Q1 		$6.34M Buy
+128,842
New +$5.96M 2.71% 14

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Altitude Crest Partners's SWTX Position: Q2 2024 in Review

Altitude Crest Partners sold out of SpringWorks Therapeutics (SWTX) in Q2 2024, closing a stake of 128,842 shares — an estimated $6.34M sold.

Altitude Crest Partners first reported a position in SWTX in Q1 2024 and held it in 1 quarter. The position peaked at $6.34M in Q1 2024. 209 funds tracked by Wall St. Rank hold SWTX as of Q2 2024.

  • Altitude Crest Partners reported no remaining SpringWorks Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 128,842 SpringWorks Therapeutics shares in Q2 2024, an estimated $6.34M.
  • Altitude Crest Partners first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's SpringWorks Therapeutics position peaked at $6.34M in Q1 2024.
  • 209 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.